Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hezhong granules is a traditional Chinese herbal medicine formula being investigated as a complementary therapy, particularly for managing symptoms associated with cancer treatment. The formula comprises eight herbs, including Pinellia ternata, Evodia rutaecarpa, and Zingiber officinale. [1, 2] Clinical studies have focused on its ability to prevent chemotherapy-induced nausea and vomiting (CINV) and its potential to improve outcomes in patients with metastatic colorectal cancer (mCRC). [2, 3] Research suggests that Hezhong granules can inhibit the release of serotonin (5-HT3) and substance P, down-regulate the neurokinin-1 receptor, and inhibit gastric secretion, contributing to its antiemetic effects. [1] Clinical trials have shown it to be effective and well-tolerated, especially in preventing delayed CINV, and it is being studied in further trials for mCRC. [2, 3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hezhong granules.